Ads
related to: acrylonitrile cancer drug
Search results
Results From The WOW.Com Content Network
An increase in cancer cases in the area was confirmed by the Turkish Medical Association, [34] as the cancer rate in the affected area has increased by 80%, from 1999 to April 2002. [33] In 2003, the owner of Aksa Akrilik died from lung cancer related to acrylonitrile exposure. [33] As of 2001, this is the largest known acrylonitrile leak. [32]
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
As examples, DNA damaging effects have been reported for acrolein, [14] formaldehyde, [15] and acrylonitrile. [16] Breast cancer is the second most frequent cancer worldwide on a yearly basis [(1.38 million cases, 10.9% of all cancer cases), and ranks 5th as cause of death (458,000, 6.1% of all cancer deaths)]. [12]
Alberts DS, Golde DW (November 1974). "DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy".Cancer Res.34 (11): 2911– 4. PMID 4424360. ...
A Michael reaction is used as a mechanistic step by many covalent inhibitor drugs. Cancer drugs such as ibrutinib, osimertinib, and rociletinib have an acrylamide functional group as a Michael acceptor. The Michael donor on the drug reacts with a Michael acceptor in the active site of an enzyme. This is a viable cancer treatment because the ...
Mr Yee was a member of the trial stage of the drug, which led to the FDA’s accelerated approval to get the drug on the market for cancer patients who have already undergone two rounds of therpy.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
In June 2024, the US FDA granted accelerated approval to adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. [10] [11]